Catalog No.: PC-38178Not For Human Use, Lab Use Only.
S-217622 (Ensitrelvir, S217622) is the first oral, non-covalent, non-peptidic SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate with biochemical IC50 of 13 nM, antiviral EC50 of 0.37 uM.
S-217622 (Ensitrelvir, S217622) is the first oral, non-covalent, non-peptidic SARS-CoV-2 3C-like protease (3CLpro) inhibitor clinical candidate with biochemical IC50 of 13 nM, antiviral EC50 of 0.37 uM.
The antiviral activity of S-217622 against SARS-CoV and SARS-CoV-2 was similar especially at the site where homology of 3CLpro was well conserved.
S-217622 also exhibited potent antiviral ability against the Middle East respiratory syndrome (MERS), human coronavirus OC43 (HCoV-OC43), and human coronavirus 229E (HCoV-229E).
S-217622 exhibited no inhibitory effect against host-cell proteases, such as cathepsin B/D/G/L, caspase-2, chymotrypsin, and thrombin at 100 uM.
S-217622 dose-dependently inhibited intrapulmonary replication of SARS-CoV-2 in mice, and currently under clincial investigation for COVID-19.
